AI startup Profluent nabs Lilly as first big pharma partner
AI start-up Profluent has signed a major alliance with pharma group Eli Lilly, worth up to $2.25bn, that will focus on gene-editing therapies.
GSK eyes October FDA verdict on chronic hep B drug
GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October.
Novartis shares fall as Entresto sales weaken
Novartis is showing the effects of its patent cliff more strongly, with generic competition hitting sales and profits in the first quarter of 2026.
Boehringer/Zealand dual-acting drug causes 16.6% weight loss
Boehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide.
Intellia files CRISPR drug after historic phase 3 readout
Intellia has reported the first-ever phase 3 results with an in vivo gene-editing therapy, CRISPR-based lonvo-z for hereditary angioedema.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Navigating Change: Key Industry Insights at PHARMAP 2026
PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor
Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...
EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery
Axtria Acquires Conexus Solutions, Uniting Agentic AI and CR...
Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, today announced the acquisition of Conexus Solutions
PHARMAP 2026: From Vendors to Strategic Partners
Strategic Partnerships at PHARMAP 2026 – Big Pharma’s Shift Toward CDMOs and CMOs
WOMA 2026: Steering the Future of Pharma Strategy
The WOMA Forum is not merely a conference. It's a convergence point for decision-makers